Company Encyclopedia
View More
name
COFOE
301087.SZ
Cofoe Medical Technology Co.,Ltd. manufactures and sells professional household medical devices in China. It offers blood pressure monitors, nebulizers, thermometers, fingertip pulse oximeters, oxygen concentrators, fetal doppler, and CPAP and BPAP devices; in vitro diagnostic products, including glucose meters, HCG test kits, H.Pylori, UTM, DNA/RNA extraction reagents, and respiratory tract infections test; wheelchair, commode chairs, hospital beds, air mattress, cane, and rollator; adult diaper and ostomy bag; and band-aids. The company also exports its products to the United States, Mexico, Chile, Germany, Spain, Italy, Turkey, the Middle East, and internationaly.
888.47 B
301087.SZMarket value -Rank by Market Cap -/-

Financial Score

22/12/2025 Update
B
Health Care EquipmentIndustry
Industry Ranking12/63
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreB
    • ROE6.77%C
    • Profit Margin10.22%B
    • Gross Margin58.22%B
  • Growth ScoreC
    • Revenue YoY5.16%C
    • Net Profit YoY21.12%B
    • Total Assets YoY1.02%C
    • Net Assets YoY0.04%C
  • Cash ScoreB
    • Cash Flow Margin978.61%B
    • OCF YoY5.16%C
  • Operating ScoreC
    • Turnover0.48C
  • Debt ScoreB
    • Gearing Ratio27.37%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    COFOE: Has participated in two strategic investments in the field of brain-computer interfaces

    On October 30th, COFOE stated during an institutional research that the company has participated in two strategic investments in the field of brain-computer interfaces. The first is an investment in NiuLingKe Medical in 2024. This company focuses on implanted brain-computer interface technology, mainly developing bionic eye and bionic ear products. The second is a recent investment in LiZhi Intelligent. This company is dedicated to the research and development of brain intelligence and robotic embodied intelligence technology, which is expected to achieve strategic synergy with the company's rehabilitation assistive products in the future, expanding intelligent rehabilitation solutions

    Wallstreetcn·
    SZ
    301087
    -0.26%
    Wallstreetcn·
    SZ
    301087
    -0.26%

    COFOE: Has launched its first ventilator mask and plans to launch a new generation of ventilators next year

    On October 30th, COFOE stated during an institutional research that the company has recently launched its first ventilator mask in terms of new product development and plans to successively launch multiple masks and a new generation of ventilator products next year. The new generation of ventilators features multiple functions such as intelligent pressure adjustment, automatic temperature and humidity regulation, blood oxygen and sleep monitoring, and supports APP and cloud connectivity, which will further improve the company's intelligent respiratory ecosystem and fill the gap in the high-end market

    Zhitong·
    SZ
    301087
    -0.26%
    Zhitong·
    SZ
    301087
    -0.26%

    Guizhou Chanhen Chemical Corporation Reports Earnings Results for the Nine Months Ended September 30, 2025

    Guizhou Chanhen Chemical Corporation reported earnings results for the nine months ended September 30, 2025. For the nine months, the company reported sales was CNY 5,804.32 million compared to CNY 3,973.47 million a year ago. Net income was CNY 964.54 million compared to CNY 672.16 million a year ago.Basic earnings per share from continuing operations was CNY 1.7132 compared to CNY 1.2448 a year ago. Diluted earnings per share from continuing operations was CNY 1.7132 compared to CNY 1.2063 a year ago.

    marketscreener·
    SZ
    002895
    +1.97%
    marketscreener·
    SZ
    002895
    +1.97%

    COFOE released its performance for the first three quarters, with a net profit attributable to the parent company of 260 million yuan, an increase of 3.30%

    According to the Zhitong Finance APP, COFOE released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 2.398 billion yuan, a year-on-year increase of 6.63%. The net profit attributable to shareholders of the listed company was 260 million yuan, a year-on-year increase of 3.30%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 222 million yuan, a year-on-year increase of 1.46%. The basic earnings per share were 1.28 yuan

    Zhitong·
    SZ
    301087
    -0.26%
    Zhitong·
    SZ
    301087
    -0.26%

    Certain A Shares of Cofoe Medical Technology Co.,Ltd. are subject to a Lock-Up Agreement Ending on 26-OCT-2025.

    Certain A Shares of Cofoe Medical Technology Co., Ltd. are under a Lock-Up Agreement until 26-OCT-2025, lasting 1472 days from 15-OCT-2021. Shareholders, including Changsha Xiezihao Medical Investments Co., Ltd. and actual controllers Zhang Min and Nie Juan, cannot transfer shares held prior to this issuance. If the share price falls below the issue price for 20 consecutive trading days within 6 months post-listing, the lockup extends by 6 months. Additionally, directors and senior management can only transfer up to 25% of their shares annually during their tenure.

    marketscreener·
    SZ
    301087
    -0.26%
    marketscreener·
    SZ
    301087
    -0.26%
    © 2025 Longbridge｜Disclaimer